Abstract
This review examines the future of metronomic chemotherapy (MCT) in the treatment of breast cancer and emphasizes its transformative potential. MCT refers to the continuous administration of a low dose of chemotherapeutic agents. It reduces toxicity, improves the quality of life, and demonstrates antitumor effects through multiple mechanisms. Although used as a stand-alone treatment for breast cancer, MCT has been combined with other therapies in recent years to further enhance its antitumor efficacy through mechanisms such as direct cytotoxicity, anti-angiogenesis, and immunomodulation. The findings of recent studies emphasize the benefits of MCT in combination with immunotherapy, endocrine therapy, and targeted therapies such as anti-human epidermal growth factor receptor 2 and anti-angiogenesis agents. Clinical trials on optimizing MCT regimens are underway. MCT is a promising approach that can revolutionize breast cancer treatment by improving patient outcomes and shifting cancer care toward a chronic disease model.